YS Biopharma announces USFDA clearance of IND Application for PIKA COVID-19 vaccine
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The company is making its entry into the Hyderabad market through its unique asset-light business model
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Revenue is up 23% whereas Profit After Tax expands 29% for the company
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Subscribe To Our Newsletter & Stay Updated